First, the core competitiveness analysis of Hainan Haiyao
1, industrial chain advantages. The layout structure of the company's industrial chain basically took shape. In terms of chemicals, the company has the production technology and ability of the whole industry chain from intermediates to raw materials to chemicals. The company will continue to optimize the production process and technology, improve technical support, in order to gain greater cost advantage, ensure the stable supply of raw materials for its own products, enhance the controllability of quality and cost, and maintain the market competitive advantage of its main products. 2. advantages of r&d. The company continues to pay attention to the research and development of raw materials, chemical pharmaceuticals, biopharmaceuticals, Chinese medicine production and medical devices. New drug research and development institutions have been established in the United States, Hong Kong, Beijing, Shanghai, Haikou and Chongqing, and monoclonal antibodies, targeted anti-tumor drugs, anti-fibrosis drugs and anti-epileptic targeted new drugs have been developed, and an interactive research and development model of innovation-optimization-imitation has been established. Taking the introduction and innovation of the first imitation product as a breakthrough, the research and development pattern of combining originality and imitation is formed around the four major fields of anti-infective drugs, anti-tumor drugs, digestive system drugs and nervous system drugs.
Second, the industry pattern and trend
With the development of world economy, the growth of population, the improvement of social aging, the drive of scientific and technological innovation and the enhancement of people's health awareness, the global pharmaceutical industry has maintained steady growth in recent years. China is the second largest pharmaceutical market in the world after the United States, and the capacity of China's pharmaceutical market will continue to increase in the next few years. With the improvement of medical demand and medical insurance system, China will become one of the countries with the fastest growth in drug consumption in the world. The pharmaceutical industry in China is still in the primary stage of development. Since China's economy entered the "new normal", on the one hand, the growth rate of output value of the pharmaceutical industry began to slow down and tend to be stable; On the other hand, the medical and health industry began to change from barbaric growth to high-quality development, and the pharmaceutical and medical device industries grew steadily, with huge room for development.
In the next few years, the policy of the pharmaceutical industry will continue to focus on the two major themes of "supply-side reform" and "price reduction", and deepen the reform of the pharmaceutical industry in terms of medical insurance fee control, two-vote system, consistency evaluation, quantity procurement, evaluation of local innovative drugs, and substitution of original research.